

# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

666 Fifth Avenue  
New York, New York 10103-3198  
FAX: (212) 318-3400

OFFICIAL  
12-14-01  
A.D.

## FACSIMILE COVER SHEET

PLEASE TRANSMIT THE FOLLOWING PAGES TO:

NAME: Examiner Amy DeCloux

COMPANY/FIRM  
(LOCATION): U.S. Patent and Trademark Office

FACSIMILE (703) 305-7401

VOICE PHONE: (703) 306-5821

From: <u>Norman D. Hanson</u>	Phone No.: <u>212-318-3168</u>	Number of Pages Sent: (Including Cover Sheet) <u>5</u>	
Date: <u>December 14, 2001</u>	User No.: <u>01030</u>	Flr: <u>24</u>	Matter No.: <u>09807811</u>
Return Transmitted Fax To: <u>Annette Crossan</u>		Internet: <u>nhanson@fulbright.com</u>	

Re:

REMARKS:

*If you experience problems with this transmission or have questions, please call 212-318-3250.*

**CONFIDENTIALITY NOTICE:** Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense. Thank you.

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office on December 14, 2001.

*Janet Crossen*  
FULBRIGHT & JAWORSKI LLP

<b>Applicant(s)</b>	:	Alexander, et al.
<b>Serial No</b>	:	09/165,546
<b>Filed</b>	:	October 2, 1998
<b>For</b>	:	ISOLATED PEPTIDES CORRESPONDING TO AMINO ACID SEQUENCES OF NY-ESO-1...
<b>Art Unit</b>	:	1644
<b>Examiner</b>	:	A. Decloux

December 14, 2001

**AMENDMENT UNDER 37 CFR § 1.111**

This amendment is submitted in response to the office action of August 6, 2001, and further to the Communication of October 24, and the telephone interview of December 11, 2001. Please amend this application as follows:

**Cancel claims 82 and 83 without prejudice. Add claims 85-87 as follows:**

**Claim 85:** A composition comprising:

- (i) a first isolated polypeptide, the amino acid sequence of which consists of the amino acid sequence set forth in SEQ ID NO: 7, and
- (ii) at least one additional polypeptide of claim 74.